Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAD328 in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa
NCT07547813Phase 2Recruiting
- Sponsor
- Almirall
- Start
- May 2026
- Primary completion
- Feb 2027
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
A Phase 2 trial of LAD328 in hidradenitis suppurativa (HS), sponsored by Almirall. Started May 2026; status: recruiting.
02
Drugs
LAD328
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT07547813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07547813.